Portal Vein Thrombosis in Cirrhosis

Corporacion Parc Tauli

Status: Withdrawn

Conditions: Cirrhosis; Hepatic Vein Thrombosis

Treatments: Other: Event of portal vein thrombosis

Study type: Observational

Funder types: Other

Identifiers

NCT02275585

CSPT2013628

Details and patient eligibility

About

This study evaluates the supervivence of cirrhotic patients that develop portal vein thrombosis in comparison to cirrhotic patients that do not develop portal vein thrombosis.

Full description

Patients newly diagnosed with portal vein thrombosis by imaging tests, that evaluate the extent and exclude tumoral origin, will be included (informed consent previously signed).

Anticoagulant treatment will be initiated according to clinical guidelines (if there is no contraindication) first with LMWH (low molecular weight heparin) and later with dicoumarin.

An abdominal CT will be performed to evaluate the extent and exclude tumoral origin; a gastroscopy to evaluate portal hypertension (and do prophylaxis if required) and thrombophilia study.

Patients will be followed by imaging and laboratory tests every 6 months; to evaluate the response to the treatment and detect any cirrhosis complication.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cirrhosis diagnosed by liver biopsy or non-invasive methods/clinical, analytics or ultrasound usual criteria
• Portal vein thrombosis of newly diagnosed (defined as partial or complete obstruction of splenoportal vessels objectified by imaging with/without symptomatology) ≤ 6 months.
• Over 18 years old
• Want to participate (informed consent)

Exclusion criteria

• Pregnant or lactating
• Patients with tumoral vein thrombosis or elevated alpha-fetoprotein or high suspicion of underlying neoplastic disease.
• Thrombocytopenia < 25.000 .
• Patients with cavernomatosis or portal vein thrombosis already known.
• Patient refusal to participate
• Patients already treated with anticoagulants for other diseases (atrial fibrillation, pulmonary thrombosis...)

Trial design

0 participants in 1 patient group

Cirrhosis

Description:

Patients with cirrhosis will be followed looking about the event of portal vein thrombosis

Treatment:

Other: Event of portal vein thrombosis